Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets

During pregnancy, islets undergo a number of up-regulatory changes to meet the increased need for insulin. One of the most important changes is an increase in glucose-stimulated insulin secretion with a reduction in the glucose-stimulated threshold. Similarly, placental lactogen and PRL induce the s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrinology (Philadelphia) 1996-05, Vol.137 (5), p.1640-1649
Hauptverfasser: Weinhaus, A J, Stout, L E, Sorenson, R L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1649
container_issue 5
container_start_page 1640
container_title Endocrinology (Philadelphia)
container_volume 137
creator Weinhaus, A J
Stout, L E
Sorenson, R L
description During pregnancy, islets undergo a number of up-regulatory changes to meet the increased need for insulin. One of the most important changes is an increase in glucose-stimulated insulin secretion with a reduction in the glucose-stimulated threshold. Similarly, placental lactogen and PRL induce the same changes in islets as pregnancy. In this study, we examined the effects of pregnancy and PRL treatment of islets in vitro on insulin secretion; glucokinase and hexokinase activities; glucokinase, hexokinase, and glucose transporter 2 protein levels; and rates of glucose utilization and oxidation. Glucokinase activity was 4.9 +/- 0.4 pmol glucose/ng DNA.h in control islets and was significantly increased by 50% in islets on day 15 of pregnancy and by 60% on day 20 of pregnancy. Hexokinase activity was 11.7 +/- 0.9 pmol glucose/ng DNA.h in control islets and was increased by 20% in islets on day 15 of pregnancy and by 90% on day 20 of pregnancy. In the in vitro studies, glucokinase activity was 7.4 +/- 0.89 pmol glucose/ng DNA.h in control islets. PRL treatment of islets in vitro increased glucokinase activity by 60%, an effect similar to that observed in the pregnancy islets. In contrast, hexokinase activity was nearly undetectable in cultured islets, whether control or PRL treated. Quantitative Western blot analysis of glucokinase and hexokinase was performed using equivalent number of protein per lane for all experimental groups. On a protein equivalency basis, glucokinase expression levels were the same in control islets on days 15 and 20 of pregnancy. Likewise, hexokinase levels were not different between control islets and islets on days 15 and 20 of pregnancy. Similarly, Western blot analysis of cultured islets indicated that there were not effect of PRL on glucokinase or hexokinase levels. However, when enzyme levels were normalized on the basis of DNA, the levels of expression appeared to be commensurate with their activities. In cultured islets, the very low level of hexokinase activity corresponded to the low level of hexokinase detected by Western blots. Glucose transporter 2, as determined by Western blot quantification, was increased 2-fold in pregnancy islets on day 15 and increased by 45% in pregnancy islets on day 20. Similar results were observed in cultured islets where glucose transporter 2 was increased 2-fold in PRL-treated islets. Islet glucose utilization and oxidation rates on day 15 of pregnancy were significantly greater than those in
doi_str_mv 10.1210/en.137.5.1640
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77996790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/en.137.5.1640</oup_id><sourcerecordid>77996790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-5dc199174b178e1d43b72792b47d179397561576dbd1214016b5213fc67fe99e3</originalsourceid><addsrcrecordid>eNpdkUFvFSEUhYnR1Gd16dKExMR00XlygRlKd6ap1aSJG10TZrjzSp2BERhjf5r_Tp59voUrIOc75wKHkNfAtsCBvcewBaG27RY6yZ6QDWjZNgoUe0o2jIFoFOfqOXmR8309SinFCTm56IBL3W3I75tpHeJ3H2zGc3qHv4773V7ISEuyIS8xFUyUn1Mb3FGasdg-Tj7P1Afq84QlU7cmH3Z0SbgLNgwPfx1LipMdig9NSWgLun909f30JcXLGjbc2VCzMh1jolOsIXXmTNelqVnrZIuPgcbxYH1Jno12yvjqsJ6Sbx-vv159am6_3Hy--nDbDILp0rRuAK1ByR7UBYKToldcad5L5UBpoVXbQas617v6nZJB17ccxDh0akStUZySd4-59Q0_VszFzD4POE02YFyzUUrrTmlWwbf_gfdxTaHezQgQTGoFXFTqzYFa-xmdWZKfbXowh0aqfvaox3U5isDMvmuDwdSuTWv2XYs_9xecYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130497123</pqid></control><display><type>article</type><title>Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Weinhaus, A J ; Stout, L E ; Sorenson, R L</creator><creatorcontrib>Weinhaus, A J ; Stout, L E ; Sorenson, R L</creatorcontrib><description>During pregnancy, islets undergo a number of up-regulatory changes to meet the increased need for insulin. One of the most important changes is an increase in glucose-stimulated insulin secretion with a reduction in the glucose-stimulated threshold. Similarly, placental lactogen and PRL induce the same changes in islets as pregnancy. In this study, we examined the effects of pregnancy and PRL treatment of islets in vitro on insulin secretion; glucokinase and hexokinase activities; glucokinase, hexokinase, and glucose transporter 2 protein levels; and rates of glucose utilization and oxidation. Glucokinase activity was 4.9 +/- 0.4 pmol glucose/ng DNA.h in control islets and was significantly increased by 50% in islets on day 15 of pregnancy and by 60% on day 20 of pregnancy. Hexokinase activity was 11.7 +/- 0.9 pmol glucose/ng DNA.h in control islets and was increased by 20% in islets on day 15 of pregnancy and by 90% on day 20 of pregnancy. In the in vitro studies, glucokinase activity was 7.4 +/- 0.89 pmol glucose/ng DNA.h in control islets. PRL treatment of islets in vitro increased glucokinase activity by 60%, an effect similar to that observed in the pregnancy islets. In contrast, hexokinase activity was nearly undetectable in cultured islets, whether control or PRL treated. Quantitative Western blot analysis of glucokinase and hexokinase was performed using equivalent number of protein per lane for all experimental groups. On a protein equivalency basis, glucokinase expression levels were the same in control islets on days 15 and 20 of pregnancy. Likewise, hexokinase levels were not different between control islets and islets on days 15 and 20 of pregnancy. Similarly, Western blot analysis of cultured islets indicated that there were not effect of PRL on glucokinase or hexokinase levels. However, when enzyme levels were normalized on the basis of DNA, the levels of expression appeared to be commensurate with their activities. In cultured islets, the very low level of hexokinase activity corresponded to the low level of hexokinase detected by Western blots. Glucose transporter 2, as determined by Western blot quantification, was increased 2-fold in pregnancy islets on day 15 and increased by 45% in pregnancy islets on day 20. Similar results were observed in cultured islets where glucose transporter 2 was increased 2-fold in PRL-treated islets. Islet glucose utilization and oxidation rates on day 15 of pregnancy were significantly greater than those in control islets at all glucose concentrations examined. This enhanced glucose sensitivity resulted in a shift of the glucose utilization and oxidation response curves to the left. Comparable results were obtained from islets on day 20 of pregnancy. PRL treatment of islets in vitro resulted in the same changes in glucose utilization and oxidation rates that were observed during pregnancy. These results demonstrate changes in glucokinase, hexokinase, and glucose transporter 2 levels and glucose metabolism that occur as islets adapt to an increased need for insulin secretion during pregnancy. The results also indicate that these same changes can be induced by PRL treatment of islets in vitro. This provides further evidence that the long term adaptive changes that occur under the normoglycemic conditions of pregnancy are mediated by lactogen-regulated events.</description><identifier>ISSN: 0013-7227</identifier><identifier>EISSN: 1945-7170</identifier><identifier>DOI: 10.1210/en.137.5.1640</identifier><identifier>PMID: 8612496</identifier><language>eng</language><publisher>United States: Endocrine Society</publisher><subject>Animals ; Blotting, Western ; Deoxyribonucleic acid ; DNA ; DNA - metabolism ; Equivalence ; Female ; Gene expression ; Glucokinase ; Glucokinase - metabolism ; Glucose ; Glucose - metabolism ; Glucose transporter ; Glucose Transporter Type 2 ; Hexokinase ; Hexokinase - metabolism ; Insulin ; Insulin - metabolism ; Insulin Secretion ; Islets of Langerhans - drug effects ; Islets of Langerhans - metabolism ; Low level ; Metabolism ; Monosaccharide Transport Proteins - metabolism ; Oxidation ; Oxidation-Reduction ; Pregnancy ; Prolactin ; Prolactin - pharmacology ; Protein transport ; Proteins ; Rats ; Rats, Sprague-Dawley ; Up-Regulation ; Utilization ; Western blotting</subject><ispartof>Endocrinology (Philadelphia), 1996-05, Vol.137 (5), p.1640-1649</ispartof><rights>Copyright © 1996 by The Endocrine Society 1996</rights><rights>Copyright © 1996 by The Endocrine Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-5dc199174b178e1d43b72792b47d179397561576dbd1214016b5213fc67fe99e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8612496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weinhaus, A J</creatorcontrib><creatorcontrib>Stout, L E</creatorcontrib><creatorcontrib>Sorenson, R L</creatorcontrib><title>Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets</title><title>Endocrinology (Philadelphia)</title><addtitle>Endocrinology</addtitle><description>During pregnancy, islets undergo a number of up-regulatory changes to meet the increased need for insulin. One of the most important changes is an increase in glucose-stimulated insulin secretion with a reduction in the glucose-stimulated threshold. Similarly, placental lactogen and PRL induce the same changes in islets as pregnancy. In this study, we examined the effects of pregnancy and PRL treatment of islets in vitro on insulin secretion; glucokinase and hexokinase activities; glucokinase, hexokinase, and glucose transporter 2 protein levels; and rates of glucose utilization and oxidation. Glucokinase activity was 4.9 +/- 0.4 pmol glucose/ng DNA.h in control islets and was significantly increased by 50% in islets on day 15 of pregnancy and by 60% on day 20 of pregnancy. Hexokinase activity was 11.7 +/- 0.9 pmol glucose/ng DNA.h in control islets and was increased by 20% in islets on day 15 of pregnancy and by 90% on day 20 of pregnancy. In the in vitro studies, glucokinase activity was 7.4 +/- 0.89 pmol glucose/ng DNA.h in control islets. PRL treatment of islets in vitro increased glucokinase activity by 60%, an effect similar to that observed in the pregnancy islets. In contrast, hexokinase activity was nearly undetectable in cultured islets, whether control or PRL treated. Quantitative Western blot analysis of glucokinase and hexokinase was performed using equivalent number of protein per lane for all experimental groups. On a protein equivalency basis, glucokinase expression levels were the same in control islets on days 15 and 20 of pregnancy. Likewise, hexokinase levels were not different between control islets and islets on days 15 and 20 of pregnancy. Similarly, Western blot analysis of cultured islets indicated that there were not effect of PRL on glucokinase or hexokinase levels. However, when enzyme levels were normalized on the basis of DNA, the levels of expression appeared to be commensurate with their activities. In cultured islets, the very low level of hexokinase activity corresponded to the low level of hexokinase detected by Western blots. Glucose transporter 2, as determined by Western blot quantification, was increased 2-fold in pregnancy islets on day 15 and increased by 45% in pregnancy islets on day 20. Similar results were observed in cultured islets where glucose transporter 2 was increased 2-fold in PRL-treated islets. Islet glucose utilization and oxidation rates on day 15 of pregnancy were significantly greater than those in control islets at all glucose concentrations examined. This enhanced glucose sensitivity resulted in a shift of the glucose utilization and oxidation response curves to the left. Comparable results were obtained from islets on day 20 of pregnancy. PRL treatment of islets in vitro resulted in the same changes in glucose utilization and oxidation rates that were observed during pregnancy. These results demonstrate changes in glucokinase, hexokinase, and glucose transporter 2 levels and glucose metabolism that occur as islets adapt to an increased need for insulin secretion during pregnancy. The results also indicate that these same changes can be induced by PRL treatment of islets in vitro. This provides further evidence that the long term adaptive changes that occur under the normoglycemic conditions of pregnancy are mediated by lactogen-regulated events.</description><subject>Animals</subject><subject>Blotting, Western</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA - metabolism</subject><subject>Equivalence</subject><subject>Female</subject><subject>Gene expression</subject><subject>Glucokinase</subject><subject>Glucokinase - metabolism</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Glucose transporter</subject><subject>Glucose Transporter Type 2</subject><subject>Hexokinase</subject><subject>Hexokinase - metabolism</subject><subject>Insulin</subject><subject>Insulin - metabolism</subject><subject>Insulin Secretion</subject><subject>Islets of Langerhans - drug effects</subject><subject>Islets of Langerhans - metabolism</subject><subject>Low level</subject><subject>Metabolism</subject><subject>Monosaccharide Transport Proteins - metabolism</subject><subject>Oxidation</subject><subject>Oxidation-Reduction</subject><subject>Pregnancy</subject><subject>Prolactin</subject><subject>Prolactin - pharmacology</subject><subject>Protein transport</subject><subject>Proteins</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Up-Regulation</subject><subject>Utilization</subject><subject>Western blotting</subject><issn>0013-7227</issn><issn>1945-7170</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUFvFSEUhYnR1Gd16dKExMR00XlygRlKd6ap1aSJG10TZrjzSp2BERhjf5r_Tp59voUrIOc75wKHkNfAtsCBvcewBaG27RY6yZ6QDWjZNgoUe0o2jIFoFOfqOXmR8309SinFCTm56IBL3W3I75tpHeJ3H2zGc3qHv4773V7ISEuyIS8xFUyUn1Mb3FGasdg-Tj7P1Afq84QlU7cmH3Z0SbgLNgwPfx1LipMdig9NSWgLun909f30JcXLGjbc2VCzMh1jolOsIXXmTNelqVnrZIuPgcbxYH1Jno12yvjqsJ6Sbx-vv159am6_3Hy--nDbDILp0rRuAK1ByR7UBYKToldcad5L5UBpoVXbQas617v6nZJB17ccxDh0akStUZySd4-59Q0_VszFzD4POE02YFyzUUrrTmlWwbf_gfdxTaHezQgQTGoFXFTqzYFa-xmdWZKfbXowh0aqfvaox3U5isDMvmuDwdSuTWv2XYs_9xecYg</recordid><startdate>19960501</startdate><enddate>19960501</enddate><creator>Weinhaus, A J</creator><creator>Stout, L E</creator><creator>Sorenson, R L</creator><general>Endocrine Society</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19960501</creationdate><title>Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets</title><author>Weinhaus, A J ; Stout, L E ; Sorenson, R L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-5dc199174b178e1d43b72792b47d179397561576dbd1214016b5213fc67fe99e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Blotting, Western</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA - metabolism</topic><topic>Equivalence</topic><topic>Female</topic><topic>Gene expression</topic><topic>Glucokinase</topic><topic>Glucokinase - metabolism</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Glucose transporter</topic><topic>Glucose Transporter Type 2</topic><topic>Hexokinase</topic><topic>Hexokinase - metabolism</topic><topic>Insulin</topic><topic>Insulin - metabolism</topic><topic>Insulin Secretion</topic><topic>Islets of Langerhans - drug effects</topic><topic>Islets of Langerhans - metabolism</topic><topic>Low level</topic><topic>Metabolism</topic><topic>Monosaccharide Transport Proteins - metabolism</topic><topic>Oxidation</topic><topic>Oxidation-Reduction</topic><topic>Pregnancy</topic><topic>Prolactin</topic><topic>Prolactin - pharmacology</topic><topic>Protein transport</topic><topic>Proteins</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Up-Regulation</topic><topic>Utilization</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weinhaus, A J</creatorcontrib><creatorcontrib>Stout, L E</creatorcontrib><creatorcontrib>Sorenson, R L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Animal Behavior Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrinology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weinhaus, A J</au><au>Stout, L E</au><au>Sorenson, R L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets</atitle><jtitle>Endocrinology (Philadelphia)</jtitle><addtitle>Endocrinology</addtitle><date>1996-05-01</date><risdate>1996</risdate><volume>137</volume><issue>5</issue><spage>1640</spage><epage>1649</epage><pages>1640-1649</pages><issn>0013-7227</issn><eissn>1945-7170</eissn><abstract>During pregnancy, islets undergo a number of up-regulatory changes to meet the increased need for insulin. One of the most important changes is an increase in glucose-stimulated insulin secretion with a reduction in the glucose-stimulated threshold. Similarly, placental lactogen and PRL induce the same changes in islets as pregnancy. In this study, we examined the effects of pregnancy and PRL treatment of islets in vitro on insulin secretion; glucokinase and hexokinase activities; glucokinase, hexokinase, and glucose transporter 2 protein levels; and rates of glucose utilization and oxidation. Glucokinase activity was 4.9 +/- 0.4 pmol glucose/ng DNA.h in control islets and was significantly increased by 50% in islets on day 15 of pregnancy and by 60% on day 20 of pregnancy. Hexokinase activity was 11.7 +/- 0.9 pmol glucose/ng DNA.h in control islets and was increased by 20% in islets on day 15 of pregnancy and by 90% on day 20 of pregnancy. In the in vitro studies, glucokinase activity was 7.4 +/- 0.89 pmol glucose/ng DNA.h in control islets. PRL treatment of islets in vitro increased glucokinase activity by 60%, an effect similar to that observed in the pregnancy islets. In contrast, hexokinase activity was nearly undetectable in cultured islets, whether control or PRL treated. Quantitative Western blot analysis of glucokinase and hexokinase was performed using equivalent number of protein per lane for all experimental groups. On a protein equivalency basis, glucokinase expression levels were the same in control islets on days 15 and 20 of pregnancy. Likewise, hexokinase levels were not different between control islets and islets on days 15 and 20 of pregnancy. Similarly, Western blot analysis of cultured islets indicated that there were not effect of PRL on glucokinase or hexokinase levels. However, when enzyme levels were normalized on the basis of DNA, the levels of expression appeared to be commensurate with their activities. In cultured islets, the very low level of hexokinase activity corresponded to the low level of hexokinase detected by Western blots. Glucose transporter 2, as determined by Western blot quantification, was increased 2-fold in pregnancy islets on day 15 and increased by 45% in pregnancy islets on day 20. Similar results were observed in cultured islets where glucose transporter 2 was increased 2-fold in PRL-treated islets. Islet glucose utilization and oxidation rates on day 15 of pregnancy were significantly greater than those in control islets at all glucose concentrations examined. This enhanced glucose sensitivity resulted in a shift of the glucose utilization and oxidation response curves to the left. Comparable results were obtained from islets on day 20 of pregnancy. PRL treatment of islets in vitro resulted in the same changes in glucose utilization and oxidation rates that were observed during pregnancy. These results demonstrate changes in glucokinase, hexokinase, and glucose transporter 2 levels and glucose metabolism that occur as islets adapt to an increased need for insulin secretion during pregnancy. The results also indicate that these same changes can be induced by PRL treatment of islets in vitro. This provides further evidence that the long term adaptive changes that occur under the normoglycemic conditions of pregnancy are mediated by lactogen-regulated events.</abstract><cop>United States</cop><pub>Endocrine Society</pub><pmid>8612496</pmid><doi>10.1210/en.137.5.1640</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0013-7227
ispartof Endocrinology (Philadelphia), 1996-05, Vol.137 (5), p.1640-1649
issn 0013-7227
1945-7170
language eng
recordid cdi_proquest_miscellaneous_77996790
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Animals
Blotting, Western
Deoxyribonucleic acid
DNA
DNA - metabolism
Equivalence
Female
Gene expression
Glucokinase
Glucokinase - metabolism
Glucose
Glucose - metabolism
Glucose transporter
Glucose Transporter Type 2
Hexokinase
Hexokinase - metabolism
Insulin
Insulin - metabolism
Insulin Secretion
Islets of Langerhans - drug effects
Islets of Langerhans - metabolism
Low level
Metabolism
Monosaccharide Transport Proteins - metabolism
Oxidation
Oxidation-Reduction
Pregnancy
Prolactin
Prolactin - pharmacology
Protein transport
Proteins
Rats
Rats, Sprague-Dawley
Up-Regulation
Utilization
Western blotting
title Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A36%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glucokinase,%20hexokinase,%20glucose%20transporter%202,%20and%20glucose%20metabolism%20in%20islets%20during%20pregnancy%20and%20prolactin-treated%20islets%20in%20vitro:%20mechanisms%20for%20long%20term%20up-regulation%20of%20islets&rft.jtitle=Endocrinology%20(Philadelphia)&rft.au=Weinhaus,%20A%20J&rft.date=1996-05-01&rft.volume=137&rft.issue=5&rft.spage=1640&rft.epage=1649&rft.pages=1640-1649&rft.issn=0013-7227&rft.eissn=1945-7170&rft_id=info:doi/10.1210/en.137.5.1640&rft_dat=%3Cproquest_pubme%3E77996790%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130497123&rft_id=info:pmid/8612496&rft_oup_id=10.1210/en.137.5.1640&rfr_iscdi=true